List of Excipients in Branded Drug NYAMYC

Generic Drugs Containing NYAMYC

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	nystatin	0832-0465	TALC
RedPharm Drug Inc	nystatin	67296-1860	TALC

What are the Most Frequently-Used Excipients in NYAMYC?

# Of NDCs	Excipient
2	TALC

NYAMYC Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

NYAMYC is a prescription nystatin topical powder containing 100,000 units of nystatin per gram. Its commercial profile is shaped by a mature active ingredient, a simple talc-based powder vehicle, limited patent protection, and demand in cutaneous and mucocutaneous candidiasis. The strongest opportunities are differentiated delivery, moisture management, lower-mess application, institutional packaging, and line extensions rather than new-molecule exclusivity.

What is NYAMYC and how does its formulation work?

NYAMYC is a topical powder for dermatologic candidiasis caused by Candida species. The product is applied to affected skin, including intertriginous areas, and is intended for external use only. Its labeled strength is 100,000 USP units of nystatin per gram. The product uses talc as the principal inactive powder base.[1]

Attribute	NYAMYC profile
Active ingredient	Nystatin
Dosage form	Topical powder
Strength	100,000 USP units/g
Route	Cutaneous topical use
Therapeutic category	Polyene antifungal
Primary indication	Cutaneous or mucocutaneous candidiasis
Prescription status	Prescription drug in the United States
Product type	Generic/ANDA-style marketed product
Principal excipient	Talc-based powder vehicle
Biosimilar exposure	None; nystatin is a small-molecule antifungal

Nystatin has negligible systemic absorption when applied to intact skin. The formulation therefore concentrates on local distribution, powder adhesion, moisture control, microbiological quality, and patient handling rather than systemic pharmacokinetics.[1,2]

What excipients protect the performance of NYAMYC?

The talc vehicle performs several functions. It dilutes nystatin to the labeled potency, supports powder flow, reduces clumping, and helps keep the treated surface dry. The excipient is operationally important because nystatin powder is used in skin folds, diaper areas, and other environments with elevated humidity.

A commercial reformulation should evaluate the following excipient functions:

Formulation function	Candidate excipient strategy	Commercial objective
Moisture absorption	Talc, starches, silica, or engineered mineral blends	Improve performance in humid skin folds
Flow and dose uniformity	Controlled particle-size talc or silica	Reduce agglomeration and improve dispensing
Skin feel	Lower-abrasion mineral blend or starch-based carrier	Reduce grittiness and improve adherence
Adhesion	Film-forming polymer or bioadhesive particulate system	Extend residence time
Odor control	Low-level compatible adsorbent	Improve patient acceptability
Dust control	Granulated powder or low-dust particle engineering	Reduce inhalation and application mess
Packaging stability	Moisture-barrier bottle, shaker, or unit-dose sachet	Protect potency and usability
Pediatric suitability	Lower-dust, soft-contact vehicle	Improve handling for infants and caregivers

The commercial risk is that each new excipient can affect nystatin potency, assay uniformity, microbial limits, particle-size distribution, delivered dose, and dermatological tolerability. A reformulation that departs materially from the reference product may require a more extensive FDA development and bioequivalence package.

What formulation patents protect NYAMYC?

The core nystatin molecule, topical use, and conventional nystatin powder technology are mature and generally outside meaningful new-molecule patent protection. The main competitive barriers are likely to be regulatory execution, manufacturing scale, distribution, and brand recognition rather than broad composition-of-matter patents.

IP category	Likely protection position
Nystatin composition of matter	Historical protection expired
Conventional nystatin topical powder	Mature technology; limited blocking value
Talc-based carrier	Generally difficult to protect broadly
Specific particle-size distribution	Potential narrow formulation claims
Moisture-control blend	Potential formulation patent opportunity
Low-dust delivery system	Potential device or formulation claims
Film-forming topical system	Potential patentable combination
Unit-dose packaging	Possible design, packaging, or utility claims
Manufacturing process	Potential trade-secret or process-patent value

A new product could seek protection around a defined excipient ratio, particle-size profile, water activity, aerosolization behavior, adhesion time, or packaging configuration. Broad claims directed only to “nystatin plus talc” would face substantial prior-art risk.

When does NYAMYC lose exclusivity?

NYAMYC does not have the exclusivity profile of a recently approved branded drug. Nystatin has been marketed for decades, and conventional nystatin topical products have long been subject to generic competition.

Exclusivity category	NYAMYC assessment
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current product-specific period identified
New clinical investigation exclusivity	Not a principal commercial barrier
Patent-based exclusivity	No broad, commercially meaningful NYAMYC exclusivity expected
Generic competition	Established or readily developable
Biosimilar competition	Not applicable

The relevant market question is therefore not the date on which NYAMYC loses exclusivity. It is whether a competitor can obtain FDA approval with acceptable product quality, demonstrate the required equivalence, and secure pharmacy or institutional distribution.

What is the FDA regulatory status of NYAMYC?

NYAMYC is an FDA-regulated prescription topical product. Nystatin topical powders are generally developed through the abbreviated pathway when a suitable reference product and applicable FDA requirements are available.[1,3]

Key regulatory issues include:

1. Active-ingredient identity and potency.
2. Uniform distribution of nystatin throughout the powder.
3. Particle-size distribution and powder flow.
4. Microbial quality.
5. Stability under humidity and temperature stress.
6. Container-closure performance.
7. Dermal irritation and sensitization risk.
8. Delivered dose from the marketed package.
9. In vitro or other product-specific equivalence requirements.

Topical products can present more complex equivalence questions than immediate-release oral tablets. The FDA may assess formulation composition, physicochemical attributes, product performance, and, where applicable, comparative clinical or pharmacodynamic evidence.[3]

What excipient changes create the best commercial opportunities?

Low-dust nystatin powder

A low-dust formulation could address caregiver concerns, application mess, and accidental inhalation. The product could use engineered particles, granulation, or a controlled-dispersion system while preserving local delivery.

The regulatory advantage is that a low-dust powder could remain close to the reference dosage form. The commercial challenge is maintaining uniform nystatin distribution after granulation and preventing reduced contact with infected skin.

Moisture-activated or moisture-retentive powder

Intertrigo and diaper candidiasis occur in high-moisture environments. A formulation that maintains powder performance after exposure to sweat or exudate could differentiate NYAMYC from conventional talc products.

Potential approaches include starch-mineral blends, controlled water activity, or excipient systems that form a thin adherent layer on contact with moisture. The formulation must avoid caking, excessive occlusion, and increased fungal growth risk in the container.

Nystatin powder with improved adhesion

Conventional powders can be displaced by friction, perspiration, clothing, or diaper changes. A lightly bioadhesive powder or powder-to-film system could extend residence time and reduce reapplication frequency.

This opportunity has greater intellectual-property potential than a simple carrier substitution. Claims could focus on adhesion duration, film formation, particle morphology, or a defined excipient combination.

Pediatric and caregiver-oriented packaging

Unit-dose sachets, metered shakers, and targeted applicators could improve dose control and reduce contamination. Packaging is especially relevant for diaper-area use, where caregivers may overapply or contaminate the container.

A packaging-led product may provide commercial differentiation without changing the active ingredient. It could also support institutional use in hospitals, long-term-care facilities, and pediatric clinics.

Combination or sequential-care products

Nystatin could be paired commercially with barrier-care products, although coformulation requires careful compatibility and regulatory analysis. Potential categories include zinc oxide barrier systems, skin protectants, and cleansers.

A fixed combination may create a more convenient product, but it also increases development complexity. The sponsor must demonstrate that the additional excipient or active ingredient does not reduce nystatin availability or alter the intended treatment profile.

How does NYAMYC compare with competing antifungal products?

NYAMYC competes with topical nystatin creams, ointments, and other antifungal products containing azoles such as clotrimazole and miconazole.

Product category	Main advantage	Main limitation	Opportunity versus NYAMYC
Nystatin cream	Familiar active ingredient; better coverage on dry skin	Greasier; less suitable for moisture management	Offer a cleaner powder or cream-powder hybrid
Nystatin ointment	Strong occlusive effect	Messy and less acceptable for broad application	Develop lower-grease topical delivery
Nystatin powder	Drying effect; useful in skin folds	Dust, poor adhesion, possible dosing variability	Improve flow, adhesion, and packaging
Clotrimazole cream	Broad consumer availability	May cause irritation in some users	Compete through prescription positioning and tolerability
Miconazole cream or powder	Broad antifungal use and retail presence	Strong branded and OTC competition	Differentiate through pediatric, institutional, or moisture-control positioning
Barrier creams	Protect skin from moisture and friction	Do not replace antifungal therapy	Pursue adjunctive or coordinated treatment products

NYAMYC has a functional advantage where moisture reduction matters. It has a usability disadvantage where patients prefer a cream, ointment, spray, or lotion with more visible coverage.

What generic entry risks exist for NYAMYC?

Generic entry risk is high at the active-ingredient level because nystatin is old, widely known, and available in multiple topical presentations. A conventional talc-based powder would likely face price competition if it matched the reference product without meaningful differentiation.

The highest-risk scenarios are:

• A low-cost nystatin powder with equivalent composition.
• A nystatin cream or ointment substituted by prescribers.
• Retail or online availability of competing antifungal products.
• Institutional conversion to lower-cost generic nystatin.
• Pharmacy substitution where the dosage form and labeling permit it.
• Manufacturer consolidation that pressures contract pricing.

The lower-risk segment is a differentiated product with a clear use-case, such as low-dust pediatric packaging, moisture-optimized intertrigo treatment, or a clinically supported adhesive powder.

Which companies are challenging NYAMYC commercially?

Competition comes from generic nystatin manufacturers, branded and generic azole manufacturers, and companies selling barrier-care products. The competitive field is fragmented because the active ingredient is mature and the dosage form is relatively simple.

The most credible competitors are manufacturers with:

• Existing FDA-approved nystatin topical products.
• Established dermatology or hospital distribution.
• Powder-filling and moisture-barrier packaging capabilities.
• Low-cost API sourcing.
• Experience with topical ANDA submissions.
• Pharmacy benefit manager and wholesaler relationships.

No biosimilar competitor is relevant because nystatin is a small-molecule antifungal, not a biologic. The principal competitive risk is generic substitution and formulation substitution, not biosimilar erosion.

What patent litigation and Paragraph IV risks affect NYAMYC?

A conventional NYAMYC-type product is unlikely to support a substantial Orange Book patent barrier. Paragraph IV risk would become relevant if a sponsor obtained approval for a newer nystatin formulation with listed patents covering a novel delivery system, excipient composition, or method of use.

Potential litigation targets would include:

• Low-dust particle-engineered nystatin.
• Nystatin powder with a defined moisture-absorption profile.
• Adhesive powder-to-film technology.
• Combination products with barrier-care actives.
• Metered-dose or targeted delivery devices.
• Specific manufacturing processes that improve content uniformity.

For the existing conventional product, commercial defense is more likely to rely on supply reliability, quality, brand familiarity, contracting, and packaging differentiation than on patent enforcement.

What licensing deals could create value around NYAMYC?

Licensing opportunities are most credible in enabling technologies rather than nystatin itself. Potential targets include:

1. Proprietary low-dust powder platforms.
2. Bioadhesive topical excipients.
3. Moisture-responsive particle systems.
4. Metered powder-dispensing devices.
5. Unit-dose packaging with contamination controls.
6. Contract manufacturing arrangements for sterile or low-bioburden topical products.
7. Regional licensing for dermatology distribution.

An asset owner could license a differentiated formulation to a generic manufacturer with an existing ANDA platform. A manufacturer could license packaging or powder-engineering technology and create a product with limited clinical development while preserving a higher price point than conventional generic powder.

How strong is the NYAMYC patent estate?

The patent estate is weak for conventional nystatin powder and potentially moderate for a genuinely differentiated delivery platform. Value depends on whether claims cover measurable product attributes that competitors cannot easily design around.

Estate component	Strategic strength
Nystatin active ingredient	Low
Talc-based powder composition	Low
Conventional topical method of use	Low
Narrow excipient ratio	Moderate if supported by performance data
Particle engineering	Moderate to strong if technically specific
Delivery device	Moderate
Manufacturing process	Moderate, with trade-secret value
Packaging configuration	Low to moderate
Clinical superiority claims	Potentially strong but costly to establish

The strongest protection would combine composition claims, process claims, performance specifications, and device claims. A single broad excipient claim would be vulnerable to invalidity and design-around strategies.

What revenue exposure and launch scenarios apply to NYAMYC?

Public product-level revenue for NYAMYC is not generally disclosed by manufacturers. Revenue exposure should therefore be modeled through unit volume, net price, channel mix, and substitution rates rather than reported brand sales.

Base generic scenario

A conventional nystatin powder competes primarily on price. Gross margins depend on API cost, powder-filling efficiency, packaging, and wholesaler discounts. This model can work at scale but has limited pricing power.

Premium convenience scenario

A low-dust or metered-dose product can command a premium if the sponsor demonstrates better handling, lower waste, and improved caregiver acceptance. The product is most suitable for pediatric, dermatology, and institutional channels.

Adjunctive-care scenario

A nystatin product paired with barrier protection or coordinated skin-care packaging could increase basket size and improve adherence. It would face higher regulatory and development complexity.

Geographic expansion scenario

The United States is a prescription market. International opportunities depend on local nystatin status, antifungal treatment guidelines, excipient restrictions, language requirements, and local registration pathways. Talc restrictions and labeling expectations vary by jurisdiction, which may favor starch-based or alternative powder systems in selected markets.

Key Takeaways

• NYAMYC is a mature nystatin topical powder containing 100,000 units/g in a talc-based vehicle.
• Conventional nystatin powder has limited patent defensibility and high generic-entry risk.
• The strongest formulation opportunities involve low dust, improved moisture management, adhesion, and controlled dispensing.
• Pediatric, caregiver, dermatology, long-term-care, and institutional channels offer the clearest commercial targets.
• Biosimilar competition is irrelevant; generic and dosage-form substitution are the main threats.
• A defensible product should combine excipient, particle-engineering, manufacturing, packaging, and device claims.
• Commercial success will depend more on regulatory execution, usability, supply reliability, and distribution than on the nystatin molecule.

FAQs

Is NYAMYC available over the counter?

NYAMYC is marketed as a prescription topical nystatin product in the United States. OTC antifungal alternatives include products containing clotrimazole, miconazole, and other permitted actives, subject to applicable FDA monograph requirements.

Can NYAMYC be reformulated as a spray?

A sprayable nystatin product is technically possible, but it would require assessment of delivered dose, suspension uniformity, nozzle performance, inhalation exposure, flammability where applicable, and topical equivalence. A spray may follow a more complex regulatory path than a closely matched powder.

Is talc necessary in a nystatin powder?

No. Talc is a conventional powder vehicle, but starches, silica-containing systems, and engineered mineral blends may be evaluated. Any replacement must preserve potency, content uniformity, flow, microbial quality, stability, and skin tolerability.

Can a nystatin powder receive new patent protection?

Potentially. Protection is more plausible for a narrowly defined formulation, particle-size distribution, moisture-response profile, adhesive system, delivery device, or manufacturing process than for nystatin combined with a conventional powder base.

Does NYAMYC have biosimilar risk?

No. Nystatin is a small-molecule antifungal. Competitive erosion would come from generic nystatin products, alternative topical dosage forms, azole antifungals, and barrier-care products.

References

1. U.S. National Library of Medicine. (n.d.). NYAMYC- nystatin powder. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Nystatin topical powder prescribing information. FDA.
3. U.S. Food and Drug Administration. (2022). Generic drug user fee amendments: Product-specific guidances for industry. FDA.